Serum sickness-like reactions in patients receiving intravenous infliximab

Gamarra, Roberto; McGraw, Steven D.; Drelichman, Vilma; Maas, Luis C.

doi:10.1016/j.jemermed.2005.01.033

Cited by 55 publications

(20 citation statements)

References 20 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delayed DHR suggestive of type IV reactions have been reported, as well as reactions suggestive of type III reactions (serum sickness-like), with symptoms such as rash, myalgia, fever, polyarthralgias, pruritus, edema, and fatigue [32,37]. Examples of the latter are DHR induced by infliximab (1 to 14 days after the infusion) and omalizumab (1 to 5 days after infusion) [38,39]. mAbs whose application is subcutaneous might elicit injection site reactions.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Bonamichi-Santos

Castells

2016

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Due to the increase in utilization of chemotherapies and antibodies, drug hypersensitivity reactions have increased dramatically worldwide, preventing the use of first-line therapies and impacting patients' survival and quality of life. Some of the more frequently used medications in cancer include taxanes for ovarian, lung, breast, and prostate cancers. Monoclonal antibodies are used in the treatment of neoplastic, autoimmune, and inflammatory diseases, and their clinical applications are becoming broader. Monoclonal antibody targets include CD20, HER-2, EGFR, IL-6 receptor, TNF-α, CD30, VEGF-A, IgE, and more, and examples of immunemediated and inflammatory diseases that respond to monoclonal antibodies include rheumatoid arthritis, Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, psoriasis and psoriatic arthritis, Wegener's granulomatosis, microscopic polyangiitis, ankylosing spondylitis, plaque psoriasis, and asthma. Neoplastic diseases include non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and colorectal, breast, gastric, and lung cancer. The clinical presentation of drug hypersensitivity reactions ranges from mild cutaneous reactions to lifethreatening symptoms including anaphylaxis. Rapid drug desensitization (RDD) has become a groundbreaking approach to the management of immediate drug hypersensitivity reactions IgE and non-IgE mediated. It is the only effective procedure that enables sensitized patients to receive the full treatment dose safely, thus representing an important advance in the patients' treatment and prognosis. The aim of this review is to provide an update on hypersensitivity reactions to commonly used monoclonal and taxanes, their clinical presentations, diagnosis, and the use of RDD for their management.

show abstract

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies

Bonamichi-Santos

Castells

2016

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

show abstract

“…In one patient series, 10% receiving the drug developed symptoms such as fever, headache, and arthralgias suggestive of serum sickness; all patients responded to steroid treatment (Hellwig et al, 2008). In addition, similar examples of serum sickness-like reactions have been reported with infliximab, a monoclonal antibody used in the treatment of Crohn disease and rheumatoid arthritis (Gamarra, McGraw, Drelichman, & Maas, 2006).…”

Section: Protracted and Delayed Reactionsmentioning

confidence: 77%

“…Recognition of the clinical presentation of delayed or serum sickness reactions are essential for early diagnosis and treatment, usually involving administration of steroids (Gamarra et al, 2006). This requires diligent assessment of patients at risk as the presenting symptom complex can be varied and can include fever, rash, and arthralgias (Todd & Helfgott, 2007).…”

Section: Delayed Reactionsmentioning

confidence: 99%

Biphasic and Delayed Hypersensitivity Reactions

Viale¹,

Yamamoto²

2010

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

Oncology nurses are well versed in the administration of chemotherapy and management of associated side effects. The side effects range from mild and easily managed to severe and potentially dose limiting, such as hypersensitivity reactions (HSRs). Although severe HSRs are not common and can be seen with any agent, some treatments or medications are associated with much higher risks, such as monoclonal antibodies. Anaphylaxis usually is uniphasic in nature; however, 20% of reactions are biphasic, with symptoms resurging after initial resolution of the original reaction. Some reactions can be delayed, occurring after repeated infusions or presenting days to weeks after the original drug administration. For specific patients, a protracted period of anaphylaxis may occur beyond 24 hours. This article describes the proposed pathophysiology for biphasic and delayed HSRs, as well as management strategies for anaphylaxis. Case reports will illustrate patient presentations for biphasic and delayed HSRs. Oncology nurses must be aware of the risk for HSRs and understand the difference in presentation for biphasic and delayed anaphylactic reactions.

show abstract

“…Delayed DHR suggestive of type IV reactions have been reported, as well as reactions suggestive of type III reactions (serum sickness-like), with symptoms such as rash, myalgia, fever, polyarthralgias, pruritus, edema, and fatigue [38,39]. Examples of the latter are DHR induced by infliximab (1 to 14 days after the infusion) and omalizumab (1 to 5 days after infusion) [40,41].…”

Section: Desensitization To Monoclonal Antibodiesmentioning

confidence: 99%